atacicept   

GtoPdb Ligand ID: 9517

Synonyms: TACI-Fc | TACI-Ig
Comment: Atacicept is a recombinant fusion protein designed to inhibit B cells, being investigated as an intervention in autoimmune diseases [1]. Mechanistically atacicept neutralises the function of two important B-cell activating factors, BAFF (BLyS) and APRIL. Structurally atacicept contains the BLyS/APRIL-binding extracellular portion of the TACI receptor fused to a modified Fc from human IgG1 [3]. One of the important functions of these two factors in autoimmune disease is their ability to induce proliferation of plasma cells and thus increase Ig production, in paticular the production of destructive anti-self antibodies.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for atacicept is claimed in patent WO2002094852 [4].
Bioactivity Comments
WO2002094852 provides binding data for BAFF but not for APRIL, ZNTF4 and ZNTF2 respectively in this patent [4].
Other ligands which bind to or alter the activity of this ligand
Key to terms and symbols Click column headers to sort
Ligand Sp. Type Action Value Parameter Concentration range (M) Reference
BAFF {Sp: Human} Hs None Binding 9.9 – 10.1 pKd - 4
pKd 9.9 – 10.1 (Kd 1.35x10-10 – 9x10-11 M) [4]
Description: Competitive binding to [125I]BAFF.